1 / 6

Hemophilia B Therapeutic Development Pipeline Review H1 2015

This report gives far reaching data on the remedial improvement for Hemophilia B, complete with relative examination at different stages, therapeutics appraisal by medication target, component of activity (MoA), course of organization (RoA) and atom sort, alongside most recent overhauls, and included news and press discharges. It additionally audits key players included in the remedial improvement for Hemophilia B and exceptional components on late-stage and suspended activities.

Ctroutman01
Download Presentation

Hemophilia B Therapeutic Development Pipeline Review H1 2015

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Hemophilia B - Pipeline Review, H1 2015 By RnRMarketResearch.com Publisher Name : Global Market Direct Date: 29-May-2015 No. of pages: 106 Single User License: US $2000 Browse more Reports on Hematology Therapeutics at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/hematology-therapeutics . ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

  2. Hemophilia B - Pipeline Review, H1 2015 This report gives far reaching data on the remedial improvement for Hemophilia B, complete with relative examination at different stages, therapeutics appraisal by medication target, component of activity (MoA), course of organization (RoA) and atom sort, alongside most recent overhauls, and included news and press discharges. It additionally audits key players included in the remedial improvement for Hemophilia B and exceptional components on late-stage and suspended activities. The report improves choice making capacities and help to make viable counter systems to increase upper hand. It reinforces R&D pipelines by distinguishing new targets and MOAs to deliver first-in-class and best-in-class items. ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

  3. Hemophilia B - Pipeline Review, H1 2015 Companies Discussed/Mentioned in this Research : Alnylam Pharmaceuticals, Inc., Amarna Therapeutics B.V., AstraZeneca PLC, Bayer AG, Biogen, Inc.,Catalyst Biosciences, Inc., CSL Limited, Dimension Therapeutics, Inc., Emergent BioSolutions Inc., Novo Nordisk A/S, OPKO Health, Inc., Pharming Group N.V., rEVO Biologics, SangamoBioSciences, Inc., Spark Therapeutics, Inc., The International Biotechnology Center (IBC) "Generium" and uniQure N.V. Drugs Profile Discussed in this Research : albutrepenonacogalfa, ALN-AT3, AMT-060, AZ-10047130, BAX-335, BAY-1093884, CB-2679d, Cell Therapy for Hemophilia B, coagulation factor IX (recombinant), coagulation factor VIIa (recombinant), concizumab, CSL-689, DTX-101, Gene Therapy for Hemophilia B, Gene Therapy to Activate Factor IX for Hemophilia B, LR-769, MOD-5014, nonacogalfa biosimilar, nonacog beta pegol, PF-05280602, Recombinant Enzyme to Replace Factor IX for Hemophilia B, SHP-624, SPK-FIX and SVF-VIIa ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

  4. Hemophilia B - Pipeline Review, H1 2015 Scope For HemophiliaB - Pipeline Review, H1 2015 • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities • The report reviews key players involved in the therapeutics development for Hemophilia B and enlists all their major and minor projects • The report summarizes all the dormant and discontinued pipeline projects • A review of the Hemophilia B products under development by companies and universities/research institutes based on information derived from company and industry-specific sources • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages • Latest news and deals relating related to pipeline products ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

  5. Hemophilia B - Pipeline Review, H1 2015 Reasons to Buy: • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage • Develop strategic initiatives by understanding the focus areas of leading companies • Identify and understand important and diverse types of therapeutics under development for Hemophilia B • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline • Devise corrective measures for pipeline projects by understanding Hemophilia B pipeline depth and focus of Indication therapeutics ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

  6. Hemophilia B - Pipeline Review, H1 2015 For more details contact Mr. Ritesh Tiwari :sales@rnrmarketresearch.com/ +18883915441 RnRMarkertResearch RnRMarketResearch.com, an online repository of market  research reports, offers in-depth analysis of over 5000 market segments. RnRMarket Research library has syndicated reports by leading market research  publishers across the globe. ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

More Related